BioCryst Pharmaceuticals Inc BCRX shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.
BofA Securities analyst Tazeen Ahmad downgraded BioCryst from a Buy rating to a Neutral rating and announced a $14 price target.
Oppenheimer analyst Justin Kim maintained BioCryst with an Outperform rating and lowered the price target from $20 to $16.
What Happened? On Friday, the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.
BioCryst discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
The company announced Monday that it will present at the 21st Annual Needham Virtual Healthcare Conference on April 14.
BCRX 52-Week Range: $9.23 - $19.99
The stock was down 7.37% at $10.30 at time of publication, according to data from Benzinga Pro.
Photo: fernandozhiminaicela from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
